Loading…
← CockpitCompetitor Analysis › NEO NeoGenomics, Inc.Open in the cockpit ↗

NeoGenomics, Inc.NEOCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Cancer-focused genetic and molecular testing laboratory serving oncologists, hospitals and pharmaceutical companies.

Momentum leader 87
Mkt cap
$1.98B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$29.1M
20-day average traded
Fwd P/E
53.5×
forward earnings
ROIC−WACC
-16.1 pp
WACC 12.8%
Hurdle
n/a
no reverse DCF
Next earnings
97 days
23 Feb 2027
Close · USD$15.29
1D+0.3%
1W-9.2%
1M-8.0%
3M-7.5%
6M+71.8%
YTD+30.0%
1Y+49.6%
ATR %5.5%
Beta1.10
52w lowhigh24.1% off high

What NeoGenomics does

Cancer-focused genetic and molecular testing laboratory serving oncologists, hospitals and pharmaceutical companies.

Clinical testing carries it: labs analyse tumour samples sent by pathologists and oncologists, and it bills the patient's insurer or Medicare for each test, so payer coverage and rates matter. A smaller pharma-services arm runs lab work for drug trials under contract. It bought Inivata in 2021 to add blood-based tests for detecting residual disease.

Products and services

  • Molecular/genomic cancer testing
  • Cytogenetics/flow cytometry testing
  • Pharma clinical trial testing services

Customers

  • Oncologists
  • Pathologists
  • Pharmaceutical/biotech companies

Where it sits in the supply chain

  • Diagnostics
  • Oncology laboratory testing
  • Genetic/molecular/cytogenetic cancer…

What could go right

  • Precision oncology testing growth
  • Pharma biomarker/trial testing demand

What could go wrong

  • Reimbursement/payer pricing pressure
  • Competitive oncology diagnostics market

Moat: narrow (scale, data). One of the largest independent cancer-testing labs, with broad test menu and pharma trial-services relationships.

Headquarters: Fort Myers, Florida · Founded: 2001 · Employees: 2,500

Named competitors

NeoGenomics at a glance

Size NeoGenomics (NEO) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.98B, the 1778th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.29 on 18 Nov 2026.

Performance Over six months the shares gained 71.8%, against +19.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 11.1% over the last twelve months (peer median +6.3%); the operating margin is -5.9% (peer median 7.5%).

Valuation It trades at 53.5× forward earnings against a peer median of 33.8× (5th most expensive of 17).

Capital Return on invested capital runs 16.1 points below its cost of capital (12.8% WACC).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026NEO 168Peer median 120
Six months, rebased to 100: NeoGenomics against the median of its 20 peers (local-currency closes).

NeoGenomics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$788M$727M$661M$592M$510M
Revenue growth—+10%+12%+16%—
Gross profit$336M$283M$257M$209M$173M
EBITDA$18.8M$1.75M$852,000-$24.1M-$71.4M
Net income-$32.3M-$108M-$78.7M-$88.0M-$144M
Free cash flow-$28.6M-$21.8M-$34.0M-$30.7M-$96.9M
Capital expenditure$32.9M$27.0M$41.1M$28.8M$30.9M
Total debt$449M$409M$605M$612M$611M

Quarterly statements and history in the cockpit →

NeoGenomics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%AZTAAGARWALEYE603882ALIF-BEMEISADUS300244VIJAYAAVAHMDPSNLSNDAAMBEAWGSAGL002044TDOC4544USPH1833NEO6-month return →1-month return →
Up and to the right = strong over both horizons. NeoGenomics is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%25×50×75×AZTAAGARWALEYE603882ALIF-BADUS300244VIJAYAAVAHMDAMBEAWGSAGL002044USPH1833NEORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. NeoGenomics is the large dot.

NeoGenomics competitors and peer comparison

Head to head with its named competitors (NEO vs LH vs DGX vs GH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
NeoGenomics NEO$1.98B+72%+11%-6%53.5×n/a
Labcorp LH$30.1B+44%+6%11%19.3×14.5%
Quest Diagnostics DGX$28.6B+34%+9%15%22.4×7.2%
Guardant Health GH$19.6B+26%+42%-39%n/an/a

How NeoGenomics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

NeoGenomics against its 20 peers (data as of 18 Nov 2026)
MeasureNEOPeer medianRank in peer set
1-month return-8.0%-0.3%6th lowest of 21
6-month return+71.8%+19.1%3rd highest of 21
Distance from 52-week high-24.1%-19.6%10th lowest of 21
Revenue growth (TTM)+11.1%+6.3%9th highest of 21
Operating margin-5.9%7.5%4th lowest of 21
Forward P/E53.5×33.8×5th most expensive of 17
ROIC minus cost of capital-16.1 pp-3.4 pp4th lowest of 20
Net debt / EBITDA16.5×1.1×2nd most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
NeoGenomics NEOUnited States$1.98B+72%+11%-6%53.5×n/an/a
Azenta AZTAUnited States$2.03B+162%+5%-2%83.2×38.0%+3.9%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%77.1×43.0%+26.9%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%
AddLife ALIF-B.STSweden$2.13B+15%+2%8%39.0×21.1%+14.6%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%16.2×4.0%+13.2%
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%21.8×0.3%-1.1%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Aveanna Healthcare AVAHUnited States$2.37B+41%+17%12%12.2×7.7%+10.2%
Pediatrix Medical MDUnited States$2.41B+37%+2%12%12.4×-4.4%+2.0%
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Meinian Onehealth Healthcare 002044.SZChina$2.60B-27%-4%9%49.6×4.2%+5.7%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%

Questions

Who are NeoGenomics's main competitors?
Named competitors: Labcorp (LH), Quest Diagnostics (DGX), Exact Sciences (private or unlisted), Guardant Health (GH). The cockpit's measured peer set (industry) also includes Azenta (AZTA), Dr. Agarwal's Health Care (AGARWALEYE.NS), Guangzhou Kingmed Diagnostics (603882.SS), AddLife (ALIF-B.ST), Emeis (EMEIS.PA), Addus HomeCare (ADUS).
Is NeoGenomics expensive compared with its peers?
On forward p/e it trades at 53.5× against a peer median of 33.8×, 5th most expensive of 17 in its peer set.
How has NeoGenomics stock performed?
Over six months to 18 Nov 2026 the shares returned +71.8% against +19.1% for the median peer; over one year +49.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.